Table 3. Primary Outcomes, Major Adverse Kidney Events at 28 Days (MAKE28) and Adverse Events by Treatment Group in Higher (>10 mg/dL) and Lower (≤10 mg/dL) Baseline Cell-Free Hemoglobin Level Groups.
| Outcomesa | High baseline cell-free hemoglobin (n = 190) | Low baseline cell-free hemoglobin (n = 240) | High vs low baseline cell-free hemoglobin | |||||
|---|---|---|---|---|---|---|---|---|
| Mean (SD) [No.] | Difference (95% CI) | Mean (SD) [No.] | Difference (95% CI) | Difference in differences (95% CI) | P value | |||
| Acetaminophen | Placebo | Acetaminophen | Placebo | |||||
| Days free to day 28 | ||||||||
| Organ support | 21.5 (10.2) [92] | 19.5 (10.6) [96] | 2.0 (−1.1 to 5.0) | 19.2 (10.9) [124] | 19.4 (10.6) [115] | −0.2 (−2.9 to 2.5) | 2.2 (−1.9 to 6.2) | .29 |
| Assisted ventilation | 22.7 (9.8) [92] | 20.2 (10.8) [96] | 2.6 (−0.4 to 5.5) | 20.6 (10.5) [124] | 20.5 (10.5) [115] | 0.1 (−2.6 to 2.7) | 2.5 (−1.5 to 6.5) | .22 |
| Vasopressors | 23.8 (8.1) [92] | 21.0 (9.9) [96] | 2.8 (0.1 to 5.5) | 21.1 (10.2) [124] | 21.3 (9.4) [115] | −0.2 (−2.6 to 2.2) | 3.0 (−0.6 to 6.6) | .11 |
| Kidney replacement therapy | 24.5 (8.7) [92] | 23.7 (8.7) [96] | 0.7 (−1.8 to 3.3) | 23.1 (9.3) [124] | 23.2 (8.8) [115] | −0.1 (−2.4 to 2.2) | 0.8 (−2.6 to 4.2) | .64 |
| All-cause mortality at 28 d, No. (%) | 11 (12.0) [92] | 20 (20.8) [96] | −8.9 (−19.4 to 1.6) | 27 (21.8) [124] | 29 (25.2) [115] | −3.4 (−14.2 to 7.3) | −5.4 (−20.5 to 9.6) | .48 |
| MAKE28, No. (%) | 20 (22.0) [91] | 22 (22.9) [96] | −0.9 (−12.9 to 11.0) | 33 (26.8) [123] | 34 (29.6) [115] | −2.7 (−14.2 to 8.7) | 1.8 (−14.8 to 18.3) | .83 |
| Any adverse events, No. of eventsb | 14 | 12 | 2 (−8 to 12) | 19 | 20 | −1 (−13 to 11) | ||
Abbreviation: MAKE28, Major Adverse Kidney Events at 28 days.
a
The percentage and mean were calculated from the nonmissing records.
b
Participants may have had more than 1 adverse event.